Results 31 to 40 of about 3,026 (154)

Impact of the use of local fidaxomicin treatment algorithms for managing Clostridium difficile infection in hospitalized patients in southeastern United States

Annals of Clinical Microbiology and Antimicrobials, 2018
Background Clostridium difficile-associated diarrhea (CDAD) is a major public health threat that results in increased length of stay, hospital readmissions, deaths, and economic burden. CDAD treatment is often guided by severity of disease.
Jonathan C. Cho, Sandy J. Estrada, Jamie J. Kisgen, Angelina Davis, Laura Puzniak   +4 more
doaj   +1 more source

A roadmap for designing narrow-spectrum antibiotics targeting bacterial pathogens

Microbial Cell, 2022
Clostridioides difficile (Cdiff) infection (CDI) continues to be the leading threat of nosocomial deaths worldwide and a major burden on health-care systems.
Xinyun Cao, Robert Landick, Elizabeth A. Campbell   +2 more
doaj   +1 more source

Controversies in the Prevention and Treatment of Clostridioides difficile Infection in Adults: A Narrative Review

Microorganisms, 2023
Clostridioides difficile remains a problematic pathogen resulting in significant morbidity and mortality, especially for high-risk groups that include immunocompromised patients.
Taryn B. Bainum, Kelly R. Reveles, Ronald G. Hall, Kelli Cornell, Carlos A. Alvarez   +4 more
doaj   +1 more source

Recurrent Clostridium difficile colitis in elderly: the role of fidaxomicin

Clinical Management Issues, 2014
Clostridium difficile colitis is a substantial cause of in-hospital morbidity. Since the mortality attributable may be as high as 10%, a prompt and effective treatment is advisable.
Francesco Artom, Valerio Del Bono
doaj   +1 more source

Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection

Gut Microbes, 2022
In fecal microbiota transplantation (FMT) against recurrent Clostridioides difficile infection (CDI), clinical outcomes are usually determined after 8 weeks. We hypothesized that the intestinal microbiota changes earlier than this timepoint, and analyzed
Shaodong Wei, Martin Iain Bahl, Simon Mark Dahl Baunwall, Jens Frederik Dahlerup, Christian Lodberg Hvas, Tine Rask Licht   +5 more
doaj   +1 more source

Controlled Delivery and Light‐Induced Release of Magic Spot Nucleotides in Escherichia coli

Angewandte Chemie International Edition, EarlyView.
We synthesized photocaged, clickable and isotope‐labeled “magic spot” Nucleotides and delivered them into Escherichia coli comparing different approaches. Light‐controlled release inside living cells enabled tracking of their conversion from pppGpp to ppGpp by capillary electrophoresis mass spectrometry and revealed their impact on the growth rate of a
Christoph Popp, Patrick Moser, Anselm Schwoerbel, Xinwei Liu, Johannes Freitag, Pinku Sarmah, Isabel Prucker, Robert Zscherp, Xuan Wang, Philipp Klahn, Hans‐Georg Koch, Gert Bange, Henning J. Jessen   +12 more
wiley   +1 more source

Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. [PDF]

PLoS ONE, 2016
BACKGROUND:We have previously shown that fidaxomicin instillation prevents spore recovery in an in-vitro gut model, whereas vancomycin does not. The reasons for this are unclear.
Caroline H Chilton, Grace S Crowther, Helen Ashwin, Chris M Longshaw, Mark H Wilcox   +4 more
doaj   +1 more source

Oral proton‐reprogrammed nanomedicine to break the inflammatory bowel disease‐Clostridium difficile infection vicious cycle

iMeta, EarlyView.
Research on the mechanism of OPR restoring intestinal epithelial cell (IEC) structure and function in inflammatory bowel disease (IBD) treatment. (A) Schematic diagram of OPR structure and the rate of GP release under different conditions. (B) Schematic diagram of OPR targeting IBD colonic lesions through charge interaction.
Wensheng Chen, Yuntao Zhang, Jue Wang, Yiming Li, Hao Wu, Qiong Huang, Wei Wu, Kelong Ai   +7 more
wiley   +1 more source

Stepwise increase of fidaxomicin in an engineered heterologous host Streptomyces albus through multi-level metabolic engineering

Synthetic and Systems Biotechnology
The anti-Clostridium difficile infection (CDI) drug fidaxomicin is a natural polyketide metabolite mainly produced by Micromonosporaceae, such as Actinoplanes deccanensis, Dactylosporangium aurantiacum, and Micromonospora echinospora.
Huang Xie, Yi-Ting Su, Qing-Ting Bu, Yue-Ping Li, Qing-Wei Zhao, Yi-Ling Du, Yong-Quan Li   +6 more
doaj   +1 more source

Clostridioides difficile Infection: Updates on Epidemiologic Patterns, Diagnostic Tools, and Treatment Modalities

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2023
Clostridioides difficile is the predominant worldwide etiology of healthcare-associated diarrhea. Furthermore, C. difficile infections (CDIs) have been designated by the Centers for Disease Control and Prevention as an urgent threat, which is the highest
Lamiaa Abd El-Fattah MADKOUR
doaj   +1 more source